Study of the Immune Response T Anti-tumoral CD4 for Patients Treated for a Metastatic Breast Cancer by Everolimus Within the Framework of Its Marketing Authorization
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- Acronyms EVERIMMUN
- 16 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 16 Oct 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2020.
- 10 Jun 2017 Biomarkers information updated